Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETECT V: Chemo vs Endocrine Therapy + HER2 Blockade + Ribociclib in HER2+/HR+ MBC
NCT02344472Phase 3Active, not recruiting
- Sponsor
- Prof. Wolfgang Janni
- Start
- Sep 2015
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ribociclib in breast cancer, sponsored by Prof. Wolfgang Janni. Started Sep 2015; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02344472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02344472.